Botulinum toxin therapy for skin disorders
Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
1. A method for treating a wart, corn, callus or bunion in a patient in need thereof, the method comprising the step of administering between 1 unit and 3000 units of a botulinum toxin to the wart, corn, callus or bunion, to thereby treat the wart, corn, callus or bunion.
2. The method of claim 1 , wherein the pain associated with said wart, corn, callus or bunion is reduced.
3. The method of claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
4. The method of claim 1 , wherein the botulinum toxin is a botulinum toxin type A.
5. The method of claim 1 , wherein the size of said wart, corn, callus or bunion is reduced.
6. The method of claim 1 , wherein the administration is by topical or subcutaneous administration of the botulinum toxin.
7. The method of claim 1 , wherein administration of a botulinum toxin type A is no less than about 1 to about 200 units per patient treatment session.
8. The method of claim 1 , wherein administration of a botulinum toxin type B is no less than about 40 to about 2500 units per patient treatment session.
9. A method for treating a symptom associated with a wart, corn, callus or bunion in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a botulinum toxin to the wart, corn, callus or bunion, thereby treating a symptom associated with the wart, corn, callus or bunion.
10. The method of claim 9 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
11. The method of claim 9 , wherein the administration is by injection directly to the a wart, corn, callus or bunion.
12. The method of claim 9 , wherein the symptom is selected from the group consisting of pain, inflammation and vascularization.
13. The method of claim 9 , wherein administration is transdermal or subdermal or intradermal.
14. The method of claim 9 , wherein the administration is by a botulinum toxin implant.
15. The method of claim 9 , wherein administration of a botulinum toxin type A is no less than about 1 to about 200 units per administration site, per patient treatment session.
16. The method of claim 9 , wherein administration of a botulinum toxin type B is no less than about 40 to about 2500 units per administration site, per patient treatment session.
17. The method of claim 9 , wherein the administration is by topical or subcutaneous administration of the botulinum toxin.